Myeloma

A three-drug combination showed both tolerability and favorable overall response rates (ORR) for patients with smoldering multiple myeloma in a phase 2 trial.

A new combination, including the immunotherapy agent Keytruda, was shown to be highly effective in treating a subset of patients with myeloma.

A novel agent showed a 78 percent response rate for patients with relapsed/refractory multiple myeloma, according to a recent phase 1 study.

A recent study looked at the relationship between obesity, MGUS and multiple myeloma.

The FDA approved a Darzalex (daratumumab) triplet for the treatment of relapsed myeloma.

There are many reasons patients don’t take their drugs for myeloma and other cancers as prescribed, but there are ways to offer support.

Thanks to recent clinical trials and FDA approvals, the treatment paradigm for multiple myeloma continues to shift.

The future of multiple myeloma treatment may be in immunotherapy combinations, according to Eric L. Smith, M.D., Ph.D.

Charles (Chuck) Wakefield, a multiple myeloma survivor and climber of the Moving Mountains for Multiple Myeloma Mount Kilimanjaro climb, discusses the importance of staying active and how he trained for the climb.

Treatment advances, including a three-drug combo, are improving outcomes for patients with myeloma.

Watch the full documentary about the Moving Mountains for Multiple Myeloma Machu Picchu climb.

​The Moving Mountains for Multiple Myeloma (MM4MM) team completed another amazing hike to raise money for the Multiple Myeloma Research Foundation (MMRF).

The recent screening of the Moving Mountains for Multiple Myeloma documentary got people asking, "Where's your Kilimanjaro?"

The Moving Mountains for Multiple Myeloma (MM4MM) team completed another amazing hike to raise money for the Multiple Myeloma Research Foundation (MMRF).

Actress Marlee Matlin shares her strategy for weathering health challenges, including her father's myeloma diagnosis.

A lone dynamo has raised a million dollars for myeloma research through amazing athletic endeavors, such as running 200 miles nonstop.

With its series of hikes, Moving Mountains for Multiple Myeloma inspires donations — and pride.

Okay, this is gonna sound complicated at first, but bear with me and let’s see if we can’t make it a bit easier… So, a diagnosis of multiple myeloma usual involves a blood test known as a “Serum Free Light Chain Assay”. not only is this test crucial…

While planning to start her family, Carmen Phaneuf learned that a cancer diagnosis may be in her future. Now, the multiple myeloma survivor urges others to live each day to the fullest.

Findings from a recent trial found that Kyprolis did not improve progression free survival (PFS) in transplant ineligible patients with newly diagnosed multiple myeloma.

A three-drug approach is proving beneficial for the treatment of multiple myeloma.

For years, Eric Gelber has been embarking on long distance runs to raise money for the Multiple Myeloma Research Foundation. This September, he will attempt his longest run yet: 200 miles through Central Park over the course of a weekend

Karuppiah Kannan, associate director at Takeda Pharmaceuticals, talks about the progress made in treating myeloma and where the field is going in the future.

Maintenance Revlimid was shown to improve overall survival in patients with multiple myeloma.

Karuppiah Kannan, associate director at Takeda Pharmaceuticals, discusses what it was like as a researcher to meet with patients during the Moving Mountains for Multiple Myeloma Grand Canyon hike.

Two phase 3 trials led to Darzalex being granted a breakthrough therapy designation by the FDA.

We were honored to present an annual evening of celebration and appreciation for the heroes that have made a difference in the lives of individuals living with multiple myeloma.

Christi Shaw may have changed her life this spring, switching from being a pharmaceutical exec to a caregiver, but one thing has stayed the same: her determination to fight cancer.

A new triplet for treating multiple myeloma may be then next new standard, according to Antonio Palumbo.

While the use of Kyprolis (carfilzomib), Pomalyst (pomalidomide) and KPd (dexamethasone) to treat some myeloma patients was "promising," researchers said that they will give the combination a closer look.